Published in Gene Therapy Weekly, August 25th, 2005
Maxygen reported a loss applicable to common stockholders of $9.9 million, or $0.28 per share, for the second quarter of 2005 compared to a loss applicable to common stockholders of $13.6 million, or $0.39 per share, in the second quarter of 2004.
As a result of the change in Maxygen's accounting for its investment in Codexis on the equity accounting basis, Maxygen does not include the operating results of Codexis in its financial statements after February 28, 2005.
Revenues in the second quarter of 2005 were $1.9 million compared to $3.6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.